<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>MIMS New Drugs RSS Feed</title>
<link>http://www.mims.co.uk/more/NewDrugs/</link>
<lastBuildDate>Sat, 25 May 2013 00:40:52 GMT</lastBuildDate>
<language>en</language>
<copyright>Haymarket © 1957 – 2009</copyright>
<image>
<title>MIMS New Drugs RSS Feed</title>
<link>http://www.mims.co.uk/more/NewDrugs/</link>
<url>http://www.mims.co.uk/_images/aqua/mimsLogo.gif</url>
</image>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1178656/Lyxumia-once-daily-injection-type-II-diabetes/</guid>
<title><![CDATA[Lyxumia: once-daily injection for type II diabetes]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1178656/Lyxumia-once-daily-injection-type-II-diabetes/</link>
<pubDate>Wed, 01 May 2013 09:20:00 GMT</pubDate>
<description><![CDATA[Lyxumia (lixisenatide) is a once-daily parenteral hypoglycaemic for the management of uncontrolled type II diabetes in combination with oral hypoglycaemics and/or insulin.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1178978/Dymista-new-intranasal-rhinitis-treatment/</guid>
<title><![CDATA[Dymista: new intranasal rhinitis treatment]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1178978/Dymista-new-intranasal-rhinitis-treatment/</link>
<pubDate>Wed, 01 May 2013 09:18:00 GMT</pubDate>
<description><![CDATA[The nasal spray Dymista is now available for the treatment of perennial and seasonal allergic rhinitis.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1178746/Perjeta-new-option-HER2-positive-breast-cancer/</guid>
<title><![CDATA[Perjeta: new option for HER2-positive breast cancer]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1178746/Perjeta-new-option-HER2-positive-breast-cancer/</link>
<pubDate>Wed, 01 May 2013 09:14:00 GMT</pubDate>
<description><![CDATA[Perjeta (pertuzumab) is licensed for HER2-positive metastatic or locally recurrent unresectable breast cancer in patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, in combination with trastuzumab and docetaxel.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1178965/Zaltrap-new-treatment-option-metastatic-colorectal-cancer/</guid>
<title><![CDATA[Zaltrap: new treatment option for metastatic colorectal cancer]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1178965/Zaltrap-new-treatment-option-metastatic-colorectal-cancer/</link>
<pubDate>Wed, 01 May 2013 09:12:00 GMT</pubDate>
<description><![CDATA[Zaltrap (aflibercept) is licensed for the treatment of metastatic colorectal cancer that is resistant to or has progressed following oxaliplatin therapy, in combination with irinotecan, 5-FU and folinic acid (FOLFIRI).]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1164511/Zoely-combined-oral-contraceptive-containing-new-progestogen/</guid>
<title><![CDATA[Zoely: combined oral contraceptive containing new progestogen]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1164511/Zoely-combined-oral-contraceptive-containing-new-progestogen/</link>
<pubDate>Wed, 01 May 2013 09:10:00 GMT</pubDate>
<description><![CDATA[Zoely is the first combined oral contraceptive to use nomegestrol as its progesterone component.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1174931/Elvanse-once-daily-treatment-option-ADHD/</guid>
<title><![CDATA[Elvanse: once-daily treatment option for ADHD]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1174931/Elvanse-once-daily-treatment-option-ADHD/</link>
<pubDate>Tue, 02 Apr 2013 09:30:00 GMT</pubDate>
<description><![CDATA[Elvanse (lisdexamfetamine) is a long-acting pro-drug stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children from 6 years of age when the response to methylphenidate is clinically inadequate.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1174889/Constella-first-in-class-treatment-option-IBS-patients-constipation/</guid>
<title><![CDATA[Constella: first-in-class treatment option for IBS patients with constipation]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1174889/Constella-first-in-class-treatment-option-IBS-patients-constipation/</link>
<pubDate>Tue, 02 Apr 2013 09:28:00 GMT</pubDate>
<description><![CDATA[Almirall has launched Constella (linaclotide) for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1174948/Vyndaqel-novel-treatment-amyloid-neuropathy/</guid>
<title><![CDATA[Vyndaqel: novel treatment for amyloid neuropathy]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1174948/Vyndaqel-novel-treatment-amyloid-neuropathy/</link>
<pubDate>Tue, 02 Apr 2013 09:26:00 GMT</pubDate>
<description><![CDATA[Pfizer has launched Vyndaqel (tafamidis) to delay peripheral neurologic impairment in patients with transthyretin familial amyloid polyneuropathy.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1165288/New-Products-2013/</guid>
<title><![CDATA[New Products 2013]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1165288/New-Products-2013/</link>
<pubDate>Tue, 02 Apr 2013 08:59:00 GMT</pubDate>
<description><![CDATA[The following products have become available for the UK market in 2013. The list below states the month they were added to MIMS.]]></description>
</item>
<item>
<guid>http://www.mims.co.uk/more/NewDrugs/rss/article/1171934/Tresiba-ultra-long-acting-insulin/</guid>
<title><![CDATA[Tresiba: ultra long-acting insulin]]></title>
<link>http://www.mims.co.uk/more/NewDrugs/rss/article/1171934/Tresiba-ultra-long-acting-insulin/</link>
<pubDate>Fri, 01 Mar 2013 10:00:00 GMT</pubDate>
<description><![CDATA[Tresiba is a once-daily basal insulin analogue with a duration of action beyond 42 hours. It is indicated for use in type 1 and type 2 diabetes.]]></description>
</item>
</channel>
</rss>
